Skip to content
You can now search across every topic, entity and event.What's new
Sofinnova Partners
OrganisationFR

Sofinnova Partners

Paris-based life-sciences VC; participant in CellCentric's £170m Series D.

Last refreshed: 13 May 2026 · Appears in 1 active topic

Timeline for Sofinnova Partners

View full timeline →
Follow UK Startups and Innovation →

Background

Sofinnova Partners participated in CellCentric's £170m Series D in May 2026 alongside lead Venrock Healthcare Capital Partners, Pfizer, Fidelity, the American Cancer Society BrightEdge vehicle, and others. CellCentric is developing inobrodib, a first-in-class p300/CBP inhibitor for relapsed multiple myeloma and prostate cancer.

Sofinnova Partners is a Paris-based life-sciences venture capital firm founded in 1972, one of the oldest dedicated biotech investors in Europe. It manages over €2.5bn in AUM across multiple funds and backs companies from early-stage through clinical proof-of-concept, with a transatlantic investment mandate spanning Europe and the US. Its portfolio includes oncology, rare disease, infectious disease, and medical devices companies. Sofinnova has offices in Paris, London, and San Francisco.

Common Questions
What is Sofinnova Partners?
Sofinnova Partners is a Paris-based life-sciences VC founded in 1972, managing over €2.5bn in AUM across oncology, rare disease, and medical devices investments in Europe and the US.Source: Sofinnova Partners
Which European VCs backed CellCentric's cancer drug round?
Sofinnova Partners was among the European investors in CellCentric's £170m Series D, Europe's largest biotech round of 2026, alongside Venrock Healthcare, Pfizer, and Fidelity.Source: Lowdown uk-startups-and-innovation U#4
Is Sofinnova one of the oldest European biotech VCs?
Yes. Sofinnova Partners was founded in 1972, making it one of the longest-established dedicated life-sciences venture firms in Europe.Source: Sofinnova Partners